Caerulein, a peptide containing seven aminoacids that is isolated from the skin of the Australian toad (Erspamer, 1970) , has been proposed as a cheaper and purer substitute for cholecystokinin-pancreozymin in the clinical testing of pancreatic exocrine function (Bonfils et al., 1971; Fox, 1972; Ribet et al., 1972) .
The purpose of the present study was to determine the optimal conditions for use of caerulein in the diagnosis of pancreatic disease by assessing the pancreatic capacity to secrete bicarbonate and particularly enzymes, by studying the effect of increasing doses of caerulein on pancreatic secretion in normal control subjects and in patients with different types of pancreatic disease.
Methods
The study involved 43 denum during the night and positioned radiologically so that the aspiration holes were sited in the descending duodenum. A nasogastric tube was sited with its tip in the antrum.
Duodenal and gastric contents were aspirated manually with intermittent insufflation of air to maintain patency of the tubes.
Four stimulant schedules were employed:
1. Thirty-one control subjects received a continuous intravenous infusion of secretin (0 5 of the patients with acute pancreatitis and pancreatic cancer (Fig. 3) . Enzyme response The separation between chronic pancreatitis and the control group was similar for lipase and chymotrypsin, with only two patients with chronic pancreatitis in whom the results overlapped with those from the controls. The overlap with amylase output was considerably greater (Fig.   4) .
The enzyme outputs of most patients recovering from acute pancreatitis and those with pancreatic carcinoma did not differ from the control.
Thus, complete overlap occurred between chronic pancreatitis, acute pancreatitis, and cancer.
No side effects were noted with any of the dose rates of secretin or caerulein, or combinations of these peptides. 
Discussion
Rates of secretion of bicarbonate equivalent to the response to 2 CU/kg-h secretin, which had previously been shown to produce maximal bicarbonate output (Ribet et al., 1971) , were obtained with all doses of caerulein combined with a background dose of Di nR /1 .h caerilein secretin (0-5 CU/kg-h). However, the enzymesecretory response obtained with 75 ng/kg-h caerulein was greater than the responses obtained with the two lower doses of caerulein; we therefore used that dose (75 ng/kg-h) of caerulein combined with 0-5 CU/kg-h secretin as a stimulant of pancreatic secretion both of bicarbonate and enzymes. This dose of caerulein was adequate to elicit a maximal enzymatic response as a higher dose resulted in an inhibition. This response was close to the maximal response elicited by cholecystokinin (Ribet et al., 1972) . When the caerulein (75 ng/kg-h) and cholecystokinin responses were compared on a molar basis the potency of caerulein was greater than that of cholecystokinin, confirming once again the greater potency of thesmaller peptides (Debas and Grossman, 1973) .
When we used this dose-combination of stimulants, excellent separation between control and chronic pancreatitis was achieved, taking both bicarbonate outputs and lipase and chymotrypsin secretion as discriminant criteria. The overlap between the outputs of amylase of the two groups precluded use of amylase secretion for diagnostic purposes. Similarly poor discrimination of amylase output between normal subjects and patients with pancreatic disease has been reported using CCK and secretin (Goldberg et al., 1972) , probably because of its great variation coefficient and its smaller increase under stimulation in health and pancreatic disease (Minaire et al., 1973) .
The discrimination between control subjects and patients with acute pancreatitis was unsatisfactory. The few patients with pancreatic carcinoma had a normal hydrelatic output with low values for the output of chymotrypsin and lipase. Thus, this result confirmed the value of the measurement of enzyme 0i.4Lps,ayae n hmtypi upt.Sm eeda i.3 =u 0nentoa nt u nyai unit).
output in the study of pancreatic disease (Burton et al., 1960; Goldberg et al., 1972; Descos et al., 1974) . While the pancreatic secretory response to a combination of caerulein and secretin cannot be used as sole criterion for the diagnosis of pancreatic carcinoma, the combination of peptides is a safe, reliable, and relatively inexpensive method of establishing the diagnosis of the pancreatic exocrine insufficiency caused by chronic pancreatitis. 
